Patients with cancer undergo surgeries and procedures for various purposes, including prophylaxis, diagnosis, staging, cure, debulking, palliation, and reconstruction. The diagnosis of cancer itself, along with the well-established complication of venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. It is also well-established that continuing patients on oral anticoagulation therapy during the periprocedural period is associated with an increased risk of bleeding. Rates of periprocedural VTE and major bleeding are significantly higher in patients with cancer, presenting a complex problem for clinicians in terms of periprocedural anticoagulation management. This article reviews the current recommendations regarding periprocedural anticoagulation management in patients with cancer. (J Natl Compr Canc Netw 2014;12:1713-1720 ticoagulation therapy during the periprocedural period is associated with an increased risk of bleeding. 4 Rates of periprocedural VTE and major bleeding are significantly higher in patients with cancer, 5 presenting a complex problem for clinicians in terms of periprocedural anticoagulation management. This article reviews the current recommendations regarding periprocedural anticoagulation management in patients with cancer with regard to the interruption and resumption of vitamin K antagonists (VKAs), unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) bridging, and target-specific oral anticoagulants (TSOACs).
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Thrombotic and Bleed Risk in the Periprocedural Period
Overall, patients with active cancer (treated within the last 6 months or receiving palliative treatment) would be considered to be at moderate risk for perioperative thromboembolism, which implies an annual risk of arterial thromboembolism (ATE) of 5% to 10% and a 1-month VTE risk of 2% to 10%. 3 However, patients with advanced-stage cancer, specific cancer histologies (ie, adenocarcinoma), high-risk biomarkers, or certain thrombogenic treatment-related factors, and those who have experienced a recent thrombotic event (within the past 3 months) or have associated severe thrombophilia (eg, protein C, protein S, or antithrombin deficiency; antiphospholipid antibodies) should be considered to be high risk for perioperative thromboembolism (annual ATE risk >10% or 1-month VTE risk >10%; Table  1 ). Finally, patients with a history of cancer and VTE greater than 12 months and no other risk factors can be considered at moderate risk. [3] [4] [5] The procedural bleeding risk can be classified into 2 groups: high risk (with a 2-day risk of major bleeding of 2%-4%) or low risk (with a 2-day risk of major bleed- Dr. Pudusseri has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Spyropoulos is a consultant for Bayer, Janssen, Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Pfizer, and is a member of the steering committee of the NHLBI Bridge Trial. 1 Patients with cancer undergo surgeries and procedures for various purposes, including prophylaxis, diagnosis, staging, cure, debulking, palliation, and reconstruction. 2 The diagnosis of cancer itself, along with its well-established association with venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. 3 It is also well-established that continuing patients on oral an-ing of 0%-2%). 6 Various surgical societies have conducted studies to determine bleeding risk based on operation type. 7 Most cardiovascular, vascular, oncologic, and urologic surgeries are considered to be associated with a high risk of bleeding. Operations and procedures associated with a low risk of bleed include cholecystectomy, abdominal hysterectomies or hernia repairs, most laparoscopic procedures, noncoronary angiography, and bronchoscopy with or without biopsy ( Table 2) . 8 No validated risk assessment models are currently available to help clinicians with periprocedural heparin bridging in patients on chronic VKAs with thromboembolic and bleeding risks. Along with thrombotic and bleeding risks, patient-and procedure-related risk factors should also be considered. A recent article by Spyropoulos and Douketis 8 presented a schematic of periprocedural antithrombotic management based on a 3-tier thromboembolic risk scheme and a 2-tier bleed risk scheme. In this conceptualized schematic, the thromboembolic risk determines whether a patient needs conservative or aggressive antithrombotic management in the periprocedural period (ie, heparin bridging). The postoperative management for initiation and duration of therapy is determined based on the procedural bleeding risk. For patients with malignancy, most procedures with low bleed risk (ie, ophthalmologic and dental procedures) warrant interruption of VKA therapy, because the bleed risk may be significant. Table 3 shows suggested periprocedural heparin bridging strategies based on thromboembolic and bleeding risks specific to patients with cancer. Other patient-specific factors, such as the development of periprocedural thrombocytopenia or anemia, fall risk, and need for supportive therapy that may affect the hemostatic system, should also be considered in management decisions for patients with cancer, especially in the postprocedural period.
Vitamin K Antagonists
The American College of Chest Physicians (ACCP) has made recommendations for VKA interruption based on the pharmacodynamic effects, specifically the time required for regeneration of vitamin K-dependent coagulation factors and the time to achieve hemostasis. 9 Therefore, for warfarin, patients would need approximately 5 days before surgery to remove any effects of the drug. On closer examination, this is a result of the 36-to 42-hour elimination half-life of warfarin; with first-order pharmacokinetics, each half-life correlates to an approximately 50% reduction in the anticoagulant effect. Thus, one half-life decreases the anticoagulant effect by approximately 50.0%, the second half-life is 25.0%, the third halflife is 12.5%, the fourth-half life is 6.25%, and the fifth half-life is 3.125%. 10 This finding was validated by studies that examined interruption of VKA therapy and used international normalized ratio (INR) on the day of surgery as a measurable outcome. In a prospective cohort study, INR testing on the day of surgery was conducted in 224 patients, all of which had stopped their warfarin 5 days prior. This study revealed that only 7% of patients had an INR greater than 1.5 on the day of surgery. Through indirect evidence, this supported the theory that discontinuation of VKAs at least 5 days before surgery allows for normalization of INR. 
Low-Molecular-Weight Heparin
Multiple studies reveal that LMWHs have superior efficacy to VKAs in patients with malignancy that require long-term VTE treatment. Romera-Villegas et al 12 found that LMWH at full dose (relative risk [RR], 0.37; 95% CI, 0.19-0.74) and intermediate dose (RR, 0.52; 95% CI, 0.35-0.79) was preferable. They also found a higher risk of recurrent VTE in patients with cancer who received a prophylactic dose of LMWH rather than a therapeutic dose. Therefore, specific considerations for the periprocedural management of patients with cancer undergoing long-term treatment with LMWHs require special review. Clinicians must consider the LMWH dose in patients with renal impairment, because LMWH is contraindicated in patients with stage V chronic kidney disease (CKD) and necessitates a dose adjustment for patients with stage IV CKD (creatinine clearance, 15-30 mL/min).
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TSOAC Use
TSOACs are a new class of drugs that is revolutionizing the management of thrombotic disorders. TSOACs can be separated into direct thrombin inhibitors, such as dabigatran, and direct factor Xa inhibitors, such as rivaroxaban and apixaban. Although the FDA approved these drugs for the prevention and treatment of VTE, the randomized controlled trials on which this approval was based included approximately 5% of patients with malignancy. The concerns are that patients with mucositis will have unpredictable absorption and a higher risk of gastrointestinal bleeding; drug interactions will occur with chemotherapeutic and hormonal agents; and there is no antidote for patients treated with TSOACs. However, guidance on the perioperative management of these patients is continually developing. 14 Additionally, studies such as the placebo-controlled pilot trial conducted by Levine et al 15 show that drugs such as apixaban were well tolerated in preventing VTE in patients undergoing chemotherapy.
Perioperative Anticoagulation Management Minor Procedures
Certain dental, dermatologic, and ophthalmologic procedures are considered to have a low bleeding risk. Randomized studies have shown that patients receiving anticoagulation treatment can be guided safely through procedures such as tooth extractions and endodontic and minor reconstructive surgery, without needing to alter their anticoagulation treatment, by using local hemostatic agents, including oxidized cellulose or an oral tranexamic acid mouthwash. 16, 17 For patients undergoing minor dermatologic procedures, certain studies found that although self-limited episodes of minor bleeding occurred with the continued use of VKA, the incidence of major bleeding was less than 5%. 18 Finally, in patients un- The time frame to discontinue LMWH before procedure and postoperative reinitiating should also apply to patients on long-term LMWH for secondary thromboprophylaxis. In high-bleed-risk procedures, intravenous UFH is preferred because of its short half-life and complete reversibility with protamine. d If bleeding continues beyond 72 h, options include a low-dose heparin bridging regimen or VKA resumption alone without postoperative bridging.
dergoing ophthalmologic procedures, similar results were seen, in that patients continuing on VKA treatment had self-limited episodes of bleeding. These bleeds did not compromise visual acuity.
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Neuraxial Anesthesia
With the introduction of neuraxial anesthesia (epidural and spinal blockades), an associated improvement in morbidity, mortality, and patient outcomes has been seen. 20, 21 However, the increasing number of patients on antithrombotic therapies warranted concerns regarding a greater risk of bleeding in patients undergoing neuraxial anaesthesia. The American Society of Regional Anesthesia and Pain Medicine (ASRA) updated guidelines in 2010 regarding the use of regional anesthesia in patients receiving antithrombotic or thrombolytic therapy. Their current recommendations for spinal or epidural anesthetic administration and catheter removal should be followed on an individual basis. The patient's coagulation status should be optimal at the time of neuraxial anesthesia administration, and any indwelling catheter should not be removed in the presence of therapeutic anticoagulation, because this can significantly increase the risk of hematoma with the potential for subsequent neurologic deficits.
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Procedures Requiring Interruption of Oral Anticoagulants
VKA Management
The current ACCP recommendation for patients who require temporary interruption of VKAs before surgery is to stop these agents approximately 5 days before surgery (grade IC evidence). Other considerations regarding the interruption of VKAs include the fact that the decay of warfarin in elderly patients may not be the same as in younger patients, 23 and that certain minor procedures that have less anticipated bleeding may require a shorter interruption. 24 Most studies have shown that resuming VKA therapy on the evening of surgery or the day after is safe. Douketis et al 25 studied 650 consecutive patients who required interruption of warfarin therapy because of an invasive procedure. In patients who underwent a non-high-bleeding-risk procedure with adequate postprocedural hemostasis, warfarin was resumed on the evening of the procedure. Other studies have shown similar results indicating that early resumption of warfarin is safe in the postoperative period.
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Use of Heparin Bridging Therapy
Intravenous UFH or LMWH Management: Perioperative management of patients who are receiving heparin bridging during temporary interruption of VKA has the potential to be complex because of multiple factors. The type of anticoagulant (intravenous UFH or LMWH), the intensity of anticoagulation (therapeutic, intermediate, or low dose), and the timing of perioperative administration are all examined.
When analyzing the intensity to prevent thromboembolism, studies have shown that low-dose LMWH or UFH is sufficient enough to prevent VTE after cancer. 28 However, evidence is still insufficient regarding whether low-dose heparin regimens are sufficient to prevent ATE. The proximity of anticoagulant interruption and resumption to surgery is also highly considered with heparin products. In patients receiving bridging anticoagulation with intravenous UFH, ACCP recommendations are to stop this treatment 4 to 6 hours before surgery. 29 Intravenous UFH would be a safer choice for patients with severe renal insufficiency or those on dialysis, because LMWH is contraindicated. Additionally, intravenous UFH can be resumed postoperatively without a bolus dose and at the same infusion rate as before procedure.
For patients receiving bridging anticoagulation with subcutaneous LMWH, the ACCP recommends administering the last preoperative dose approximately 24 hours before surgery. 9 When contemplating initiation of LMWH postprocedure, it has been well documented that the closer to surgery LMWH is given, the greater the potential of its anticoagulant effect. 30, 31 Thus, although Table 3 depicts a suggested LMWH bridging protocol, clinicians should always assess postoperative hemostasis and delay LMWH bridging with a therapeutic dose until after adequate hemostasis is achieved. Finally, the principles of stopping and restarting LMWH for patients on long-term LMWH follows the same protocol as for those who are on VKA therapy receiving LMWH bridging.
TSOAC Management
For any TSOAC-treated patient, perioperative management is maintained by the following factors: elimination half-life of the TSOAC being used, the patient's renal function, and the planned surgery and its high or low risk of bleed. 32 Postoperative resump-tion of these TSOACs are based on 3 factors: their rapid onset of action, the potential effect of postoperative bowel dysmotility, and the use of acidsuppressive therapy on drug absorption of these TSOACs. 33 Dabigatran has an elimination half-life of 14 to 17 hours in patients with normal or mild renal impairment. Therefore, in patients undergoing a procedure with a high bleed risk, the last dose should be given 3 days before surgery. Based on the dosing of dabigatran at 150 mg twice daily, these patients would be skipping 4 doses. In patients with moderate renal impairment, dabigatran has a half-life of 16 to 18 hours, and therefore the last dose should be given 5 days before surgery (ie, skip 8 doses). 34 The cessation of rivaroxaban and apixaban also depends on the drug elimination half-lives. For rivaroxaban, the half-life is 8 to 9 hours, and for apixaban it is 7 to 8 hours. A patient's renal function is also a factor, because the renal clearance is 33% for rivaroxaban and is 25% for apixaban. 35 Both rivaroxaban and apixaban should be discontinued at least 3 to 4 days for procedures with a high bleeding risk. Typically, for patients with more-severe renal impairment, 4 days is necessary. In procedures with a low bleeding risk, 2 to 3 days should suffice.
For postoperative resumption of rivaroxaban and apixaban, clinicians should base reinitiation on bleeding risk and whether hemostasis was achieved. In patients undergoing major surgery, a lower dose of rivaroxaban at 10.0 mg daily or apixaban at 2.5 mg twice daily may be a safer option for the first 2 to 3 days, with treatment dose regimen for the following days. Table 4 shows suggested perioperative management of dabigatran, rivaroxaban, and apixaban based on renal function and bleeding risk.
Conclusions
The periprocedural management of patients with cancer on chronic oral anticoagulant therapy is a common and complex challenge faced by clinicians. Patient-related factors, such as histologic type and stage of malignancy and concomitant risk factors for thrombosis, can complicate this matter greatly. Clinicians must take into consideration not only these factors but also procedural-related risk factors for bleeding. Patients with cancer can be classified into high or moderate risk for perioperative thromboembolism based on factors such as recent VTE, concurrent thrombophilia, and active cancer or chemotherapy treatment. The periprocedural bleeding risk can be classified into high or low risk. Thus, it is helpful to conceptualize a 3-tiered thromboembolism risk scheme and a 2-tiered bleed risk scheme when assessing patients with cancer who will require periprocedural anticoagulation. Certain minor procedures may not require temporary interruption of oral anticoagulant therapy. In procedures requiring interruption of VKA, the current recommendation is to discontinue treatment 5 days before surgery. Studies have shown that it is safe to resume VKA therapy on the day of surgery or the next day. In any patient with cancer undergoing a procedure with a high risk for bleeding, the current recommendations are to use either intravenous UFH or to use LMWH as bridging therapy, usually in treatment doses. In low-bleedrisk situations, LMWH can be restarted within 24 hours of the procedure, whereas in high-bleed-risk situations, postoperative initiation of anticoagulation with therapeutic-dose LMWH should not be restarted before 48 to 72 hours. In patients with cancer who have a moderate thromboembolic risk, heparin bridging will depend on patient-and surgical-related risk factors for bleeding and thrombosis.
Although much research is still needed in patients with malignancy who are on TSOACs, perioperative management is guided by the half-life of individual TSOACs, renal function of the patient, and operative surgical risk. Further clinical work is needed to establish best practices for patients with cancer who are receiving antithrombotic therapy and require surgery.
